| Nov 13 |
Inovio Pharmaceuticals Q3 2024 Earnings Preview
|
| Nov 13 |
Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial
|
| Nov 6 |
INOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024
|
| Oct 21 |
INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP
|
| Oct 16 |
Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?
|
| Oct 9 |
Inovio (INO) Surges 6.8%: Is This an Indication of Further Gains?
|
| Oct 1 |
INOVIO to Present at Upcoming Scientific Conferences
|
| Sep 30 |
Inovio Pharmaceuticals: Takes Another Torpedo But Keeps On Sailing
|
| Sep 17 |
INOVIO to Present at Upcoming Scientific Conference
|
| Aug 11 |
We Think Inovio Pharmaceuticals (NASDAQ:INO) Needs To Drive Business Growth Carefully
|
